151 related articles for article (PubMed ID: 33777398)
1. Anti-TIF1γ antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers.
Imai R; Ikemura S; Jinta T
Respirol Case Rep; 2021 Apr; 9(4):e00736. PubMed ID: 33777398
[TBL] [Abstract][Full Text] [Related]
2. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
3. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
5. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis.
Nakanishi Y; Yamaguchi K; Yoshida Y; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Miyamoto S; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Intern Med; 2020 Oct; 59(20):2553-2558. PubMed ID: 32581161
[TBL] [Abstract][Full Text] [Related]
6. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
7. Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.
Zhang S; Chen YL; Liu CL; Xie JY; Sun BD; Liu DZ
Front Immunol; 2022; 13():757802. PubMed ID: 35185871
[TBL] [Abstract][Full Text] [Related]
8. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
9. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
10. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
11. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
13. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
[TBL] [Abstract][Full Text] [Related]
14. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
17. Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.
Aritomi T; Kido T; Nakano K; Satoh Y; Noguchi S; Jotatsu T; Hanaka T; Satoh M; Tanaka Y; Yatera K
Intern Med; 2019 Feb; 58(3):427-431. PubMed ID: 30210109
[TBL] [Abstract][Full Text] [Related]
18. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
19. Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.
Karino K; Fujieda Y; Kawamura T; Abe N; Shimoyama S; Kono M; Kato M; Yasuda S; Atsumi T
Medicine (Baltimore); 2018 Dec; 97(49):e13563. PubMed ID: 30544475
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis.
Kato T; Ito S; Tsuzuki T; Watanabe D; Kubo A; Yamaguchi E
Respirol Case Rep; 2019 May; 7(4):e00412. PubMed ID: 30906559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
